SAN DIEGO , Oct. 19, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing of a private placement of 3,360,000 shares of its common stock at a price of $6.00 per share.

Data Highlight Advantages of CD101 in Difficult-to-Treat Infections SAN DIEGO , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies

SAN DIEGO , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer of Cidara, is scheduled to present at two

SAN DIEGO , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., the company’s president and chief executive officer, will participate in a keynote

Exclusive pricing program designed to drive uptake of T2 Biosystems' products and accelerate enrollment in Cidara's CD101 trials, targeting deadly sepsis-causing pathogen Candida LEXINGTON, Mass. and SAN DIEGO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc.

SAN DIEGO , Aug. 09, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended June 30, 2017 and provided an update on its corporate activities and

Data published in Antimicrobial Agents and Chemotherapy demonstrate CD101 has superior tissue and lesion penetration compared to the current standard of care SAN DIEGO --(BUSINESS WIRE)--Aug. 1, 2017-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives

SAN DIEGO --(BUSINESS WIRE)--Jul. 6, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer, will be participating in a panel discussion at

Panel Discussion Will Highlight Urgent Needs and Opportunities in Antifungal Development SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein ,

Data Highlight Expanded Utility of CD101 for Potential Treatment and Prevention of Serious Fungal Infections SAN DIEGO --(BUSINESS WIRE)--May 30, 2017-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that